1
|
Frega G, Kepp O, Turchetti D, Rizzo A, Pantaleo MA, Brandi G. Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms. Transl Oncol 2021; 14:101224. [PMID: 34592590 PMCID: PMC8482038 DOI: 10.1016/j.tranon.2021.101224] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 08/31/2021] [Accepted: 09/10/2021] [Indexed: 11/30/2022] Open
Abstract
The genetic background and the antigenic landscape of cancer cells play a critical role in the response to immunotherapies. A high tumor antigenicity, together with an increased adjuvanticity potentially induced by a peculiar type of cell death, namely immunogenic cell death (ICD), could foster the response to immunogenic therapies. The gestational trophoblastic neoplasm (GTN) is a one-of-a-kind cancer in the oncological landscape due to its exclusive genomic makeup. The prognosis of GTN is significantly better than non-gestational trophoblastic neoplasm (nGTN). Due to its peculiar genetic inheritance, GTN potentially constitutes a singular archetype in the immuno-oncological field.
Collapse
Affiliation(s)
- G Frega
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy.
| | - O Kepp
- Equipe labellisée par la Ligue contre le cancer, INSERM UMR1138, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
| | - D Turchetti
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; U.O. Genetica Medica, Policlinico S. Orsola-Malpighi, Centro di Ricerca sui Tumori Ereditari, Bologna Italy
| | - A Rizzo
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy
| | - M A Pantaleo
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy
| | - G Brandi
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy
| |
Collapse
|
2
|
Rizzo A, Frega G, Palloni A, Piemontese A, Di Federico A, Ricci A, Carloni R, Fabbri F, Novelli M, Tavolari S, Di Marco M, Ravaioli M, Brandi G. P-69 Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
3
|
Rizzo A, Ricci A, Frega G, Palloni A, Dall'Olio F, Lorenzo SD, Tavolari S, Abbati F, Vasuri F, Di Marco M, Tober N, Nigro M, Mosca M, Mollica V, Maggio I, Tovoli F, Cescon M, Serra C, Ambrosini V, Nanni C, Fanti S, Brandi G. PD-2 Role of pretreatment SUVmax on 18F-FDG PET and clinicopathological features in the prognostic stratification of newly diagnosed intrahepatic cholangiocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Frega G, Tavolari S, Indio V, Deserti M, Tarantino G, Palloni A, De Lorenzo S, Rizzo A, Astolfi A, Brandi G. Potentially actionable mutations in intrahepatic cholangiocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Tavolari S, Deserti M, Vasuri F, Curti S, Palloni A, Pinna AD, Cescon M, Frega G, De Lorenzo S, Barbera MA, Garajova I, Ricciardiello L, Malvi D, D'Errico-Grigioni A, Pantaleo MA, Brandi G. Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments. Eur J Cancer 2018; 106:160-170. [PMID: 30528800 DOI: 10.1016/j.ejca.2018.11.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 10/26/2018] [Accepted: 11/01/2018] [Indexed: 12/27/2022]
Abstract
Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. hENT-1 was recently reported to have a predictive role in intrahepatic cholangiocarcinoma (iCC) patients receiving adjuvant gemcitabine-based chemotherapy, but its biological and clinical significance in iCC remains unsettled. This study investigated the role of hENT-1 in regulating tumour growth and predicting the survival of 40 resected iCC patients not receiving adjuvant treatments. hENT-1 expression was found to be significantly higher in iCC than in the matched non-tumoural liver. Patients harbouring hENT-1 localised on the tumour cell membrane had a worse overall survival than membrane hENT-1-negative patients (median 21.2 months vs 30.3 months, p = 0.031), with an adjusted hazard ratio of 2.8 (95% confidence interval 1.01-7.76). Moreover, membrane hENT-1-positive patients had a higher percentage of Ki67-positive cells in tumour tissue than membrane hENT-1-negative patients (median 23% vs 5%, p < 0.0001). Functional analyses in iCC cell lines revealed that hENT-1 silencing inhibited cell proliferation and induced apoptosis in HUH-28 cells expressing hENT-1 on the cell membrane, but not in SNU-1079 cells expressing the transporter only in the cytoplasm. Overall, these findings suggest that membrane hENT-1 is involved in iCC proliferation and associated with worse survival in resected iCC patients. Further prospective studies on larger cohorts are required to confirm these results and better define the potential prognostic role of membrane hENT-1 in this setting of patients.
Collapse
Affiliation(s)
- S Tavolari
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - M Deserti
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - F Vasuri
- "F. Addarii" Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - S Curti
- Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A Palloni
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A D Pinna
- Division of Surgery and Transplantation, S. Orsola- Malpighi University Hospital, Bologna, Italy
| | - M Cescon
- Division of Surgery and Transplantation, S. Orsola- Malpighi University Hospital, Bologna, Italy
| | - G Frega
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - S De Lorenzo
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - M A Barbera
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - I Garajova
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - L Ricciardiello
- Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - D Malvi
- "F. Addarii" Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A D'Errico-Grigioni
- "F. Addarii" Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - M A Pantaleo
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy.
| |
Collapse
|
6
|
Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. J Bone Oncol 2018; 12:33-37. [PMID: 30042924 PMCID: PMC6054714 DOI: 10.1016/j.jbo.2017.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 11/18/2017] [Accepted: 11/24/2017] [Indexed: 10/24/2022] Open
Abstract
•Natural history of biliary cancers metastatic to bone•The role of skeletal events in patients with biliary cancer•Biliary cancer and bone metastases: role of bisphosphonates.
Collapse
Affiliation(s)
- D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Aprile
- Department of Oncology, San Bortolo Hospital, ULSS8 Berica–East District, Vicenza, Italy
- Department of Oncology, University and General Hospital, Udine, Italy
| | - M Russano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - S Cereda
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - F Leone
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - S Lonardi
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - L Fornaro
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - M Scartozzi
- Medical Oncology, Hospital & University of Cagliari, Italy
| | - N Silvestris
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - S Barni
- Medical Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047 Treviglio, Bergamo, Italy
| | - F Pantano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - A Palloni
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Frega
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - M Casagrande
- Department of Oncology, University and General Hospital, Udine, Italy
| | - L Ferrari
- Department of Oncology, University and General Hospital, Udine, Italy
| | - V Dadduzio
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Intini
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Filippi
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - E Vasile
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - C Vivaldi
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - L Faloppi
- Medical Oncology, Hospital of Macerata, Macerata, Italy & Medical Oncology, University of Cagliari, Italy
| | - O Brunetti
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - M Reni
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - M Aglietta
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| |
Collapse
|
7
|
Filippi R, Frega G, Vivaldi C, Casadei Gardini A, Aprile G, Silvestris N, Satolli M, Faloppi L, Santini D, Lutrino E, Vasile E, Valgiusti M, Basile D, Brunetti O, Spadi R, Russano M, Scartozzi M, Cagnazzo C, Brandi G, Leone F. Biliary tract carcinoma and chronic viral hepatitis in Italy: the GICO (Gruppo Italiano COlangiocarcinoma) experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Abbati F, Massucci M, Mollica V, Palloni A, Barbera M, Frega G, Ferracin M, Porcellini E, Brandi G, Biasco G, Garajová I. Focus on metastatic right-sided colon cancer: the best overall response to the first-line non-EGFR treatment correlates with better overall survival. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Massucci M, Francesca A, Veronica M, Palloni A, Frega G, Ferracin M, Porcellini E, Brandi G, Biasco G, Garajová I. Radically resected stage III colorectal cancer: sidedness and prognosis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Palloni A, Barbera M, Frega G, Abbati F, Biasco G, Garajova I. Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.32] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Abbati F, Barbera M, Palloni A, Frega G, Biasco G, Garajova I. The overall survival of patients affected by metastatic colorectal cancer before and after “monoclonal antibodies era”: a monocentric retrospective study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Barbera M, Frega G, Palloni A, Abbati F, Biasco G, Garajova I. Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|